SNDX News and Press, Syndax Pharmaceuticals Inc. From 12/10/22

Summary How informed are you about binding interactions of Menin with the mixed lineage leukemia 1 protein for the treatment of acute myeloid leukemia? Neither am I. This analysis has been supported by the Institutional Investing community who has the resources and intensity to set mark...

Syndax Pharmaceuticals ( NASDAQ: SNDX ) prices an underwritten public offering of 6.82M shares. The public offering price of each share of common stock is $22.00. Aggregate gross proceeds are expected to be ~$150M. Underwriters a 30-day option to purchase up to an addition...

Syndax Announces Pricing of $150 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass. , Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...

Syndax Pharmaceuticals ( NASDAQ: SNDX ) on Tuesday announced that it plans to offer and sell $150 million of shares of its common stock in an underwritten public offering. Shares -7.1% after the bell. Syndax said it also expects to grant the underwriters a 30-day option to...

Syndax Announces Proposed $150 million Public Offering of Common Stock PR Newswire WALTHAM, Mass. , Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing a...

Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia PR Newswire -- Revumenib is the first and only investigational treatment for R...

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology PR Newswire – Treatment with axatilimab resulted in an overall response rate (ORR) of 67% across all pat...

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer PR Newswire WALTHAM, Mass. , Dec. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative...

Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference PR Newswire WALTHAM, Mass. , Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipelin...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation